Xiangxue Pharmaceutical (300147) — Net Asset Quality Index
Xiangxue Pharmaceutical (300147) has a Net Asset Quality Index of -1.3% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥6.66 Billion minus total liabilities of CN¥6.75 Billion yields net assets of CN¥-84.09 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check financial resilience of Xiangxue Pharmaceutical to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Xiangxue Pharmaceutical Net Asset Quality Index Over Time (2007–2025)
This chart shows how Xiangxue Pharmaceutical's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at -1.3%, representing net assets of CN¥-84.09 Million against total assets of CN¥6.66 Billion CNY. See how liquid is Xiangxue Pharmaceutical's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Xiangxue Pharmaceutical (2007–2025)
The table below presents the year-by-year Net Asset Quality Index for Xiangxue Pharmaceutical from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Xiangxue Pharmaceutical market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 0.7% | CN¥43.95 Million | CN¥6.75 Billion | CN¥6.70 Billion | ▼ -18.5 pp |
| 2024 | 19.2% | CN¥1.44 Billion | CN¥7.50 Billion | CN¥6.06 Billion | ▼ -8.7 pp |
| 2023 | 27.9% | CN¥2.31 Billion | CN¥8.28 Billion | CN¥5.97 Billion | ▼ -2.2 pp |
| 2022 | 30.1% | CN¥2.82 Billion | CN¥9.35 Billion | CN¥6.53 Billion | ▼ -2.9 pp |
| 2021 | 33.0% | CN¥3.76 Billion | CN¥11.38 Billion | CN¥7.62 Billion | ▼ -10.5 pp |
| 2020 | 43.5% | CN¥4.25 Billion | CN¥9.78 Billion | CN¥5.53 Billion | ▼ -5.1 pp |
| 2019 | 48.6% | CN¥4.11 Billion | CN¥8.46 Billion | CN¥4.35 Billion | ▲ +2.1 pp |
| 2018 | 46.5% | CN¥4.01 Billion | CN¥8.63 Billion | CN¥4.61 Billion | ▲ +5.4 pp |
| 2017 | 41.1% | CN¥3.88 Billion | CN¥9.44 Billion | CN¥5.56 Billion | ▼ -5.0 pp |
| 2016 | 46.1% | CN¥3.68 Billion | CN¥7.99 Billion | CN¥4.30 Billion | ▼ -30.1 pp |
| 2015 | 76.2% | CN¥3.55 Billion | CN¥4.65 Billion | CN¥1.11 Billion | ▲ +24.1 pp |
| 2014 | 52.1% | CN¥1.87 Billion | CN¥3.59 Billion | CN¥1.72 Billion | ▲ +2.9 pp |
| 2013 | 49.2% | CN¥1.71 Billion | CN¥3.47 Billion | CN¥1.76 Billion | ▼ -2.9 pp |
| 2012 | 52.1% | CN¥1.54 Billion | CN¥2.95 Billion | CN¥1.41 Billion | ▼ -21.8 pp |
| 2011 | 73.9% | CN¥1.42 Billion | CN¥1.92 Billion | CN¥502.16 Million | ▼ -0.4 pp |
| 2010 | 74.2% | CN¥1.37 Billion | CN¥1.85 Billion | CN¥476.01 Million | ▲ +25.9 pp |
| 2009 | 48.3% | CN¥337.62 Million | CN¥698.31 Million | CN¥360.69 Million | ▲ +12.7 pp |
| 2008 | 35.6% | CN¥196.54 Million | CN¥551.47 Million | CN¥354.94 Million | ▲ +1.0 pp |
| 2007 | 34.6% | CN¥191.45 Million | CN¥553.43 Million | CN¥361.98 Million | — |